Mucoepidermoid carcinoma is the commonest primary malignant salivary gland tumor in both children and adults and constitutes around 2.8-16% of all salivary gland tumors. There is a wide age range of 3 to 95 years with a mean age of 47 years. We reported a case of 85 years old female patient, who presented to the department of Surgical Oncology, Srinivasan Medical College and Hospital, Trichy, with history of right parotid swelling for past 25 years, who had undergone Superficial parotidectomy 10 years back, followed by recurrence of tumor with huge increase in size, around 20 cm in greatest dimension. Right Completion Radical Parotidectomy with Modified Radical neck dissection type 1 with Cervical Rotation Flap cover was done and histopathological examination of the surgical specimen confirmed as high grade Mucoepidermoid carcinoma. Following surgery, the patient's outcome is better, uneventful with periodic regular follow-up.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10447321 | PMC |
| http://dx.doi.org/10.1007/s12070-023-03566-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Androgen receptor overexpression by immunohistochemistry in malignant salivary gland tumors in Tanzania.
BMC Cancer
January 2025
Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Background: Malignant salivary gland tumors (SGTs) present diagnostic challenges and limited treatment options. This study aims to determine the proportion of malignant SGTs overexpressing the androgen receptor (AR) by immunohistochemistry (IHC) and its association to age, sex, anatomical site, histopathological subtype and grade which may inform customized treatment approaches.
Methodology: This was a retrospective cross-sectional analytical study of archived paraffin embedded tissue blocks of malignant SGTs diagnosed at MNH Central Pathology Laboratory (CPL) from January 2019 to December 2022.
The role of irisin and cytokines in the etiology of parotid tumors.
Biotech Histochem
January 2025
Department of Ear Nose and Throat, Firat University Faculty of Medicine, Elazig, Turkey.
This study explores the role of irisin and interleukins in parotid tumors by determining the tissue staining intensity of irisin, the salivary and plasma levels of irisin, and the plasma levels of IL-4, IL-6, IL-10 and TNF-alpha in individuals with parotid tumors. Forty-eight patients and forty healthy individuals were included to the study and allocated into four group. Benign Group I (pleomorphic adenoma), Group II (Warthin's tumor), Group III (mucoepidermoid carcinoma) and Group IV (benign parotid control group, healthy control group).
View Article and Find Full Text PDFRelative Frequency of Primary Salivary Gland Tumors: Multicenter Study of 796 Cases from Riyadh, Saudi Arabia.
Medicina (Kaunas)
December 2024
King Abdulaziz Medical Center, National Guard Health Affairs, Riyadh 21423, Saudi Arabia.
Salivary gland tumors (SGTs) are diverse lesions with varying morphological and clinical characteristics. Limited data exist on the distribution of SGTs in Saudi Arabia. We aimed to fill this gap by examining the distribution of SGTs across four tertiary hospitals in Riyadh.
View Article and Find Full Text PDFFrom asthma exacerbation to pulmonary mucoepidermoid carcinoma: A rare case report.
Int J Surg Case Rep
December 2024
Department of Pathology, Al-Istishari Hospital, Ramallah, Palestine.
Introduction And Importance: Pulmonary mucoepidermoid carcinoma (PMEC) is a rare lung tumor, accounting 0.1-0.2 % of lung malignancies, commonly affecting adults under 50.
View Article and Find Full Text PDFDefining the needle in a haystack: A compendium of genomic, pathologic, and clinical characteristics of rare pulmonary tumors.
Lung Cancer
December 2024
Department of Internal Medicine, Division of Hematology/Oncology, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine (IUSOM), Indianapolis, IN 46202, USA. Electronic address:
A major paradigm shift in the diagnosis, management, and survival outcomes of early and advanced non-small cell lung cancer has transpired over the past few decades in thoracic oncology with the incorporation of molecular testing, targeted therapy, immunotherapy, neoadjuvant, and adjuvant approaches. However, transformation in the management and survival outcomes of rare lung tumors is lacking. Given the scarcity of these tumor types, randomized trials are rarely performed, and treatment is extrapolated from case series, tumor-agnostic trials, or cancers with similar histology.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!